Who is sponsoring UPDATE?

UPDATE is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

What condition does UPDATE study?

UPDATE studies Atopic Dermatitis Eczema, Atopic Dermatitis.

What drugs are being tested in UPDATE?

Interventions: NB-UVB phototherapy, Optimal topical therapy.

What is the status of UPDATE?

UPDATE is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2026-01-22 · How we verify

The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema): A Multicenter Randomized Controlled Trial of Narrowband UVB Versus Optimized Topical Therapy in Patients With Atopic Eczema

NCT05704205 NA ACTIVE_NOT_RECRUITING

The goal of this randomized controlled trial is to study the (cost)effectiveness of NB-UVB phototherapy in patients with atopic eczema/atopic dermatitis. Half of the participants will undergo a course of NB-UVB phototherapy of 8-16 weeks and apply optimal topical therapy (OTT) for a minimum of 3 months. Researchers will compare the outcomes of this group with the other half of participants that apply OTT only.

Details

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase	NA
Status	ACTIVE_NOT_RECRUITING
Enrolment	316
Start date	2023-02-22
Completion	2026-12

Conditions

Atopic Dermatitis Eczema
Atopic Dermatitis

Interventions

NB-UVB phototherapy
Optimal topical therapy

Primary outcomes

Percentage of patients that reach EASI50 — 3 months
Percentage of patients that reach a 50% reduction of the EASI (Eczema Area and Severity Index) at 3 month follow-up

Countries

Netherlands